BioCentury | Feb 27, 2020
Product Development

Feb. 26 Quick Takes: Takeda acquires PvP for celiac therapy; plus Lilly, Esperion, Supernus, Moderna, Taiho-Arcus, Twist-Sophia

Takeda gains another celiac candidate via PvP takeout   After PvP Biologics Inc. finished a Phase I trial demonstrating proof of concept of its celiac disease therapy, Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) exercised its...
BC Innovations | Dec 10, 2019
Emerging Company Profile

Zentalis debuts with trio of clinical oncology programs, $85M series C

Zentalis emerged from stealth Monday with an untranched and oversubscribed $85 million series C and three internally discovered clinical cancer candidates, with plans to begin pivotal testing by 2021. The C round syndicate includes Matrix...
BC Innovations | Oct 31, 2019
Distillery Therapeutics

Allosteric inhibitor of PGAM1 identified for NSCLC

DISEASE CATEGORY: Cancer INDICATION: Non-small cell lung cancer (NSCLC) A benzenesulfonamide-based allosteric inhibitor of PGAM1, given alone or in combination with the EGFR inhibitor Tarceva erlotinib, could treat NSCLC. Structure-based optimization of a previously reported...
BioCentury | Sep 14, 2019
Product Development

Success in lung cancer niches will hinge on access to next-gen sequencing

New targeted lung cancer therapies against RET, KRAS and c-MET are all outperforming standard of care in the clinic, including checkpoint inhibitors. But whether these therapies see uptake will likely depend more on whether next-generation...
BC Innovations | Aug 23, 2019
Distillery Therapeutics

KRAS inhibitor combinations for improved therapeutic efficacy

DISEASE CATEGORY: Cancer INDICATION: Lung cancer, pancreatic cancer UCSF’s Kevan Shokat and colleagues have identified two sets of genes for which inhibition could improve the efficacy of KRAS G12C inhibitors. Through a CRISPR-based screen in...
BC Extra | Aug 9, 2019
Clinical News

AZ notches another win in cancer with Tagrisso in NSCLC

AstraZeneca continued its momentum of positive cancer news this summer as Tagrisso osimertinib showed a survival benefit in first-line NSCLC. AstraZeneca plc (LSE:AZN; NYSE:AZN) said the oral irreversible inhibitor of EGFR activating mutations significantly improved...
BC Innovations | Apr 22, 2019
Distillery Therapeutics

Combined inhibition of EGFR and RAF1 for mutant-KRAS, mutant TP53-driven PDAC

DISEASE CATEGORY: Cancer INDICATION: Pancreatic cancer Cell culture and mouse studies suggest dual inhibition of EGFR and CRAF could help treat KRAS- and p53-mutant pancreatic ductal adenocarcinoma (PDAC). In nine patient-derived KRAS- and p53-mutant PDAC...
BC Week In Review | Mar 15, 2019
Clinical News

Lilly looks to expand Cyramza's label into first-line NSCLC

Eli Lilly said it plans to initiate global regulatory applications mid-year seeking to expand the label of Cyramza ramucirumab to include first-line treatment of metastatic non-small cell lung cancer in patients whose tumors have activating...
BC Week In Review | Dec 14, 2018
Financial News

Versant launches Black Diamond to mine allosteric mutant oncogenes

Black Diamond Therapeutics Inc. (New York City, N.Y.) emerged from stealth on Dec. 11 with $20 million in a tranched series A round from Versant Ventures and a platform to find and drug allosteric mutant...
BC Extra | Dec 11, 2018
Financial News

Versant launches Black Diamond to mine allosteric mutant oncogenes

Black Diamond Therapeutics Inc. (New York City, N.Y.) emerged from stealth on Tuesday with $20 million in a tranched series A round from Versant Ventures and a platform to find and drug allosteric mutant oncogenes...
Items per page:
1 - 10 of 887